Thoracic Spinal Versus Thoracic Epidural Anesthesia for Patients with Chronic Obstructive Pulmonary Disease Undergoing Supine Percutaneous Nephrolithotomy for Management of Renal Stones.
NCT ID: NCT06663488
Last Updated: 2024-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2023-08-15
2024-10-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with COPD have a wide range of options for anesthesia, depending on illness stage, type of surgery, and length of operation. General anesthesia (GA) is known to increase the risk of problems for patients with COPD, especially when paired with endotracheal tube insertion and mechanical ventilation. Increased risk of hypoxemia and intra- and postoperative pulmonary complications; laryngospasm; bronchospasm; lung barotrauma; hemodynamic instability; hypercarbia; prolonged postoperative mechanical ventilation; and difficulty in weaning. To address these challenges, there has been a growing inclination towards employing various forms of regional anesthetic techniques whenever possible, including central neuraxial block. This approach aims to minimize the risks associated with general anesthesia and its potential complications, providing a safer alternative for COPD patients undergoing different types of surgical procedures. Regional blocking, as opposed to GA, has been found to improve pulmonary outcomes in patients with severe COPD and patients with normal lung function.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Erector Spinae Block vs Conventional Analgesia for Postoperative Analgesia in PCNL
NCT06935006
Comparison of the Interscalene Block Alone Versus Combined With Superior Truncus Block During Shoulder Surgery in Diaphragmatic Function
NCT07338630
Ultrasound-assisted Spinal Anesthesia in Midline Versus Paramedian Approach in Adult Orthopedic Surgery
NCT07047469
Comparison of Efficacy of Intercostal Nerve Block vs Peritract Infiltration With 0.25% Bupivacaine in PCNL
NCT04835922
Fractionated Spinal Anesthesia With Combined Isobaric and Hyperbaric Bupivacaine for Elderly Hip Fracture Patients
NCT07288996
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Materials and methods:
After approval of the Scientific Research Ethical Committee, Faculty of Medicine, Sohag University, written informed consent will be taken from all patients.
Inclusion criteria:
\- One hundred patients 45-80 years of age, with ASA physical status classes (II and III) complaining of COPD scheduled for various electives (PNL) for renal stone. All patients knew that they had COPD with stages I-III (mild to severe airflow limitation) with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) less than 70% of the normal value.
Exclusion criteria:
Patients reject neuraxial anesthesia and prefer GA. Local back infection. Lumbar or thoracic spine deformity. Coagulopathy or platelet dysfunction. Diabetic patients with peripheral or central neurological dysfunction. Pulmonary artery systolic pressure greater than 50 mmHg. Obesity (BMI \>30). ASA physical status class less than III. PaCO2 of more than 45 mmHg and PaO2 of less than 60 mmHg on room air.
-Patients with allergy to local anesthetic (LA) drugs. On arrival at the operative room, a wide-bore peripheral intravenous line and a central line were inserted. Base level central venous pressure was recorded and then 500 ml lactated Ringer's solution was given. Arterial line penetration into the radial artery of the non-dependent arm for arterial blood gas (ABG) sampling and invasive blood pressure monitoring after ensuring a positive Allen test. ECG, pulse oximetry, noninvasive blood pressure, respiratory rate (RR), skin temperature, and the flow rate of urine were included in the monitoring.
Patients were randomly assigned into two equal groups, 50 patients in each.
First group: Thoracic spinal anesthesia (TSA group):
This group received segmental thoracic spinal anesthesia, first antiseptic preparation for cleaning the skin, then 1% lidocaine infiltrating the skin at the puncture site. Patients were put in a lateral decubitus or sitting position and puncture was performed via paramedian approach at the intersection of T5-T6 or T6-T7 in all patients with a 27G cutting needle (GMS). The needle's stylet was removed and the hub was observed for free flow of CSF; once the flow of clear CSF,4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected. The patient was then placed in the supine position.
The second group: Thoracic epidural anesthesia (TEA Group) The epidural needle will be as inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered to the epidural catheter in 4 ml split aliquots at 5 min intervals after confirmation of catheter position. The bilateral sensory block in both midclavicular lines was tested every 2 minutes for loss of pinprick sensation. After 15 min, an additional 3-5 ml of bupivacaine was administered if the sensory block level was still below T5. Epidural anesthesia was retained when one-fourth to one-third of the initial LA dose was injected.
IF sensory regression occurred in two parts. For postoperative analgesia, epidural infusion of a mixture of 0.125 percent bupivacaine at a rate of 6-10 ml/h was maintained, with infusion rate adjustment according to VAS and side effects.
Oxygen was supplied to all patients by a nasal catheter at a rate of 2 L/min. Intraoperative hypotension \[mean arterial pressure (MAP) \<20% of preoperative value\] was treated with intravenous 5 mg ephedrine in increments, Bradycardia \[heart rate (HR) \<55 beat/min\] was treated with 0.5-2 mg intravenous atropine and the vomiting was treated by intravenous 10 mg metoclopramide. After surgery, all patients were transferred into the surgical PACU for monitoring, clinical evaluation, and management of any problem.
Supplemental epidural injections will be administered in aliquots of 5 ml isobaric bupivacaine 0.5% only if sensory block reseeds below the T5 dermatome, and systemic drugs cannot control the pain.
Intraoperative irritability was treated with re-assurance and midazolam bolus of 1-2 mg intravenously. Conversion to GA was done in cases where the surgeons faced a technical difficulty of the surgery or in case of lack of patient satisfaction with regional anesthesia at any time during the procedure.
Data that was recorded;
1. Patient's demographic data (age, body weight, sex ratio, ASA PS classes, duration of surgery, and blood loss).
2. Technical ease of the needle insertion and catheter threading through it. The degree of ease is classified as very easy, easy, difficult, and very difficult.
3. VAS score for pain as the postoperative analgesia was assessed by the VAS every 2 h.
4. Motor blockade was evaluated by the modified Bromage scale before starting the surgery, motor block at the end of the surgery, block regression in minutes (0 the patient can flex the extended leg at the hip, 1 can flex the knee but cannot flex the extended leg, 2 cannot move foot only, 3 cannot move foot).
5. Hemodynamic changes: HR and MAP, preoperatively (baseline values), intraoperatively every 5 minutes until the first 30 minutes then every 15 minutes until 4 hours, and postoperatively at 1 h after surgery,
6. Respiratory changes: RR (min), PaCO2 (mmHg), and PaO2 (mmHg) preoperatively (baseline values), intraoperatively at 30 min, 1 h, at end of surgery, and postoperatively at 1 h after surgery
7. The incidence of various side effects such as hypotension (MAP\<20% of baseline value), bradycardia (HR\<55 b/m), vomiting, pruritus, respiratory depression (RR\<8 breath/min.
8. The patient was discharged from the postanesthetic care (PACU) after total regression of the block, provided that postoperative pain will be well controlled by systemic analgesics; in the form of ketolorac 30 mg IV, paracetamol 1 g IV, and/or nalbuphine 5-20 mg IM whenever needed. Epidural catheters were removed just prior to patients' discharge to their respective wards.
9. Patient and surgeon satisfaction was evaluated by using a four-point scale (4 is excellent, 3 is good, 2 is satisfactory, and 1 is poor), and the length of ICU stay. Pain severity was evaluated via VAS postoperatively at 2, 6, 12, and 24 h.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Thoracic spinal anesthesia
Thoracic spinal anesthesia: at T5-T6 or T6-T7 level with a 27G with 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine
Thoracic spinal anesthesia
Thoracic spinal anesthesia: At T5-T6 or T6-T7, a 27G needle was inserted. The needle's stylet will be removed and the hub observed for free flow of CSF; once flow of clear CSF, 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected
thoracic epidural anesthesia
Thoracic epidural anesthesia: The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine will be injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was injected
Thoracic epidural anesthesia
The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered .
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thoracic epidural anesthesia
The epidural needle was inserted At T6-8 space, After verification of the epidural space by resistance loss technique, a test dose of 2 ml of 0.5% bupivacaine was injected. In the Cephalad direction, the epidural catheter was threaded 3 cm into the epidural space. A total dose of 8-12 ml 0.5 percent plain bupivacaine was administered .
Thoracic spinal anesthesia
Thoracic spinal anesthesia: At T5-T6 or T6-T7, a 27G needle was inserted. The needle's stylet will be removed and the hub observed for free flow of CSF; once flow of clear CSF, 4 ml of isobaric bupivacaine 0.5% plus 0.5 ml of 250 ug morphine was injected
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients known that they had COPD with stages I-III (mild to severe airflow limitation) with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) less than 70% of the normal value.
Exclusion Criteria
* Local back infection.
* Lumbar or thoracic spine deformity.
* Coagulopathy or platelet dysfunction.
* Diabetic patients with peripheral or central neurological dysfunction.
* Pulmonary artery systolic pressure greater than 50 mmHg.
* Obesity (BMI \>30).
* ASA physical status class less than III.
* PaCO2 of more than 45 mmHg and PaO2 of less than 60 mmHg on room air.
* Patients with allergy to local anesthetic (LA) drugs.
45 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fouad Soliman
Principal investigator. Lecturer of Anesthesiology and ICU
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University
Sohag, Sohag Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.